2nd dose-felt weak; 2nd dose-starting to get flu like symptoms; 2nd dose-hot at injection site; hardness at injection site; 2nd dose-covid arm; Swelling at injection site; 2nd dose-Redness; itching at injection site; 2nd dose- asthma attack; This spontaneous case was reported by a consumer and describes the occurrence of ASTHENIA (2nd dose-felt weak), INFLUENZA LIKE ILLNESS (2nd dose-starting to get flu like symptoms), VACCINATION SITE WARMTH (2nd dose-hot at injection site), VACCINATION SITE MASS (hardness at injection site) and ASTHMA (2nd dose- asthma attack) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 020F21A and 039D21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Allergy (medical allergies.). Concomitant products included ALBUTEROL [SALBUTAMOL], BUDESONIDE, FORMOTEROL FUMARATE (SYMBICORT) and IPRATROPIUM BROMIDE, SALBUTAMOL SULFATE (DUONEB) for Asthma, AMITRIPTYLINE for Bladder pain, ISOSORBIDE MONONITRATE for Heart failure (NOS), ATENOLOL, AMLODIPINE and LOSARTAN for Hypertension, LEVOTHYROXINE for Thyroid disorder, FENOFIBRATE for Triglycerides, METFORMIN for Type 2 diabetes mellitus, CLOPIDOGREL BISULFATE (PLAVIX) for an unknown indication.   On 08-Sep-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Oct-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 06-Oct-2021, the patient experienced ASTHMA (2nd dose- asthma attack). On 07-Oct-2021, the patient experienced VACCINATION SITE WARMTH (2nd dose-hot at injection site), VACCINATION SITE MASS (hardness at injection site), VACCINATION SITE REACTION (2nd dose-covid arm), VACCINATION SITE SWELLING (Swelling at injection site), VACCINATION SITE ERYTHEMA (2nd dose-Redness) and VACCINATION SITE PRURITUS (itching at injection site). On 08-Oct-2021, the patient experienced ASTHENIA (2nd dose-felt weak) and INFLUENZA LIKE ILLNESS (2nd dose-starting to get flu like symptoms). The patient was treated with IPRATROPIUM BROMIDE, SALBUTAMOL SULFATE (DUONEB) for Asthma, at an unspecified dose and frequency; HYDROCORTISONE for Adverse event, at an unspecified dose and frequency and DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) for Adverse event, at an unspecified dose and frequency. At the time of the report, ASTHENIA (2nd dose-felt weak), INFLUENZA LIKE ILLNESS (2nd dose-starting to get flu like symptoms), VACCINATION SITE WARMTH (2nd dose-hot at injection site), VACCINATION SITE MASS (hardness at injection site), ASTHMA (2nd dose- asthma attack), VACCINATION SITE REACTION (2nd dose-covid arm), VACCINATION SITE SWELLING (Swelling at injection site), VACCINATION SITE ERYTHEMA (2nd dose-Redness) and VACCINATION SITE PRURITUS (itching at injection site) had not resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment medications includes ice. Concomitant medications includes Plavix indication blood thinner, fenofibrate indication triglyceride, Isosorbide MN ER indication heart.   This case was linked to MOD-2021-351051 (Patient Link).